导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.89% | 2920/4773 |
| 近一周 | -1.82% | 2939/5465 |
| 近一月 | -3.64% | 2712/5421 |
| 近一季 | -7.18% | 2706/5231 |
| 近半年 | -2.94% | 2329/4920 |
| 近一年 | 0.40% | 2705/4394 |
| 近两年 | 43.23% | 1758/2954 |
| 近三年 | 25.41% | 1294/2253 |
| 成立以来 | 80.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.46% 3223/4961 |
11.75% 2301/5312 |
- - |
- - |
| 2025 | 18.25% 2330/4813 |
-0.98% 2507/3635 |
1.88% 2045/4076 |
17.37% 2523/4524 |
-0.14% 2381/4813 |
| 2024 | 16.18% 836/3463 |
2.61% 742/2808 |
-1.19% 971/3014 |
16.58% 1413/3129 |
-1.71% 1804/3463 |
| 2023 | -9.13% 1113/2656 |
4.38% 967/2280 |
-4.00% 1007/2385 |
-3.02% 827/2515 |
-6.49% 1800/2655 |
| 2022 | -19.06% 797/2207 |
-13.77% 833/1919 |
6.70% 627/2016 |
-13.64% 938/2113 |
1.86% 1111/2208 |
| 2021 | -3.17% 891/1822 |
-3.00% 738/1255 |
4.09% 923/1330 |
-5.46% 807/1466 |
1.44% 933/1822 |
| 2020 | 28.93% 550/1250 |
-9.57% 689/1028 |
13.21% 640/1067 |
11.63% 432/1164 |
12.81% 429/1184 |
| 2019 | 37.10% 343/1092 |
26.94% 370/754 |
-0.01% 208/804 |
0.92% 445/850 |
7.04% 499/918 |
| 2018 | -22.64% 253/834 |
- - |
- - |
- - |
-11.87% 372/691 |
| 2017 | 22.65% 144/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.05% 254/605 |
- - |
- - |
- - |
- - |
| 2015 | 6.46% 191/575 |
- - |
- - |
- - |
- - |
| 2014 | 52.25% 67/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.71% 102/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.79% 48/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 农银沪深300指数A VS. 长安沪深300非周期A(740101) |